相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting triple-negative breast cancer: optimising therapeutic outcomes
K. Gelmon et al.
ANNALS OF ONCOLOGY (2012)
Targeting the S and G2 checkpoint to treat cancer
Tao Chen et al.
DRUG DISCOVERY TODAY (2012)
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
Cynthia X. Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Otto Metzger-Filho et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
Paula M. Fracasso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Molecular heterogeneity of triple-negative breast cancer and its clinical implications
Sheeba Irshad et al.
CURRENT OPINION IN ONCOLOGY (2011)
p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features
Elia Biganzoli et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Cynthia X. Ma et al.
TRENDS IN MOLECULAR MEDICINE (2011)
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Yun Dai et al.
CLINICAL CANCER RESEARCH (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress
Van Leung-Pineda et al.
CANCER RESEARCH (2009)
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Farrah Kassam et al.
CLINICAL BREAST CANCER (2009)
Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer
Corey Speers et al.
CLINICAL CANCER RESEARCH (2009)
p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer
Byung Joo Chae et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The F Box Protein Fbx6 Regulates Chk1 Stability and Cellular Sensitivity to Replication Stress
You-Wei Zhang et al.
MOLECULAR CELL (2009)
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
Antonio Jimeno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
Berengere Marty et al.
BREAST CANCER RESEARCH (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2-: Breast carcinomas
Lieve Verlinden et al.
CANCER RESEARCH (2007)
Targeting checkpoint kinase 1 in cancer therapeutics
Archie N. Tse et al.
CLINICAL CANCER RESEARCH (2007)
Modulation of cell cycle progression in human tumors: A pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)
Raymond P. Perez et al.
CLINICAL CANCER RESEARCH (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Genotoxic stress targets human Chk1 for degradation by the ubipuitin-proteasome pathway
YW Zhang et al.
MOLECULAR CELL (2005)
PDK1, the master regulator of AGC kinase signal transduction
A Mora et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2004)
Cell cycle checkpoints and their impact on anticancer therapeutic strategies
A Eastman
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
EA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
Z Xiao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A
CS Sorensen et al.
CANCER CELL (2003)
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints
H Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Protein kinases: Getting NEKed for S6K activation
DJ Templeton
CURRENT BIOLOGY (2001)
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens
Y Shigeoka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative
XJ Xie et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines
A Monks et al.
INVESTIGATIONAL NEW DRUGS (2000)
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
PR Graves et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest
CB Jones et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
分享论文
